The hospital will use the SOPHiA DDM™ Platform
to enhance its testing and research of blood cancers
BOSTON and ROLLE, Switzerland, July 29,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native healthcare technology company and a leader in
data-driven medicine, today announced that L'hôpital
Universitaire Avicenne is implementing the SOPHiA DDM™ Platform.
The hospital, located in Bobigny, France, will use the platform to advance its
testing and research of blood-related cancers and
disorders.
L'hôpital Avicenne, which serves approximately 500,000 patients
annually across all areas of care, is a clinical, research, and
teaching hospital, known for its expertise in oncology. L'hôpital
Avicenne's clinical hematology department treats various
hematological malignancies via 25 in-patient beds and outpatient
care.
"As a research and teaching hospital, as well as a clinical
center of excellence, it is our goal to offer all of our patients
advanced and personalized care," said Grégory Lazarian, PhD,
Medical Biologist L'Hôpital Avicenne. "By implementing the SOPHiA
DDM™ Platform we will be able to expand our lymphoid testing,
which will advance research and treatment planning for blood
disorders and cancers."
Blood cancers are the fifth most common type of cancer in the
world with roughly 1.3 million new cases reported
annually.1 Advances in the study of blood cancers, as
with many other cancers, depend on timely, cost-effective, and
reliable sequencing strategies as well as high-quality and
reproducible data. The SOPHiA DDM™ Platform uses next-generation
sequencing (NGS) to target key variants from FFPE, blood, or bone
marrow samples helping lead to better detection of variants
associated with the disease. SOPHiA DDM™ is specifically designed
to compute a wide array of genomic variants and continually hone
machine learning algorithms to detect genomic variants associated
with rare and challenging cases.
"At SOPHiA GENETICS we are passionate about accelerating and
expanding the use of precision medicine. This is made possible by
our AI-based technology that facilitates fast and accurate analysis
of key data and helps draw relevant insights for researchers and
clinicians to support them in making data-driven decisions," said
Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS.
"L'hôpital Avicenne, like many of our customers, is focused on
delivering the most accurate and advanced care to each patient, and
we are confident the implementation of our SOPHiA DDM™ Platform
will support them in this commitment."
The SOPHiA DDM™ Platform delivers results that are nearly 100
percent2 reproducible to provide consistent inter-
and intra-run results, ensuring stable and trustworthy
sequencing data. For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to
data-driven medicine by using AI to deliver world-class care to
patients with cancer and rare disorders across the globe.
It is the creator of the SOPHiA DDM™ Platform, which analyzes
complex genomic and multimodal data and
generates real-time, actionable insights for a broad
global network of hospital, laboratory, and biopharma
institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1
https://www.worldwidecancerresearch.org/news-opinion/2022/september/blood-cancer-everything-you-need-to-know/
2 99.3% observed
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-lhopital-universitaire-avicenne-is-live-on-sophia-ddm-302208684.html
SOURCE SOPHiA GENETICS